Herpes simplex virus and human papillomavirus genital infections: new and investigational therapeutic options

Human papillomavirus and Herpes simplex virus are the most common genital viral infections encountered in clinical practice worldwide. We reviewed the literature focusing on new and experimental treatment modalities for both conditions, based on to the evidence‐based data available. The modalities e...

Full description

Saved in:
Bibliographic Details
Published in:International journal of dermatology 2010-07, Vol.49 (7), p.733-749
Main Authors: Viera, Martha H., Amini, Sadegh, Huo, Ran, Konda, Sailesh, Block, Samantha, Berman, Brian
Format: Article
Language:English
Subjects:
Antiviral Agents - therapeutic use
Biological and medical sciences
Cidofovir
Condylomata Acuminata - drug therapy
Condylomata Acuminata - immunology
Data processing
Dermatology
Drug Design
foscarnet
Herpes Genitalis - drug therapy
Herpes Genitalis - immunology
Herpes simplex virus
Human papillomavirus
Human viral diseases
Humans
imiquimod
Immune response
Infection
Infectious diseases
Interferon
Medical sciences
Oligonucleotides
Papillomavirus Infections - drug therapy
Papillomavirus Infections - immunology
Penciclovir
Reviews
Vaccines
Viral diseases
Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Human papillomavirus and Herpes simplex virus are the most common genital viral infections encountered in clinical practice worldwide. We reviewed the literature focusing on new and experimental treatment modalities for both conditions, based on to the evidence‐based data available. The modalities evaluated include topical agents such as immune response modifiers (imiquimod, resiquimod, and interferon), antivirals (penciclovir, cidofovir, and foscarnet), sinecatechins, microbiocidals (SPL7013 gel, and PRO 2000 gel), along with experimental (oligodeoxynucleotides), immunoprophylactic, and immunotherapeutic vaccines.
ISSN:0011-9059
1365-4632
DOI:10.1111/j.1365-4632.2009.04375.x